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Abstract
Background
Bariatric surgery is becoming a more widespread treatment for obesity. Comprehensive evi-
dence of the long-term effects of contemporary surgery on a broad range of clinical out-
comes in large populations treated in routine clinical practice is lacking. The objective of this
study was to measure the association between bariatric surgery, weight, body mass index,
and obesity-related co-morbidities.
Methods and Findings
This was an observational retrospective cohort study using data from the United Kingdom
Clinical Practice Research Datalink. All 3,882 patients registered in the database and with
bariatric surgery on or before 31 December 2014 were included and matched by propensity
score to 3,882 obese patients without surgery. The main outcome measures were change
in weight and body mass index over 4 y; incident diagnoses of type 2 diabetes mellitus
(T2DM), hypertension, angina, myocardial infarction (MI), stroke, fractures, obstructive
sleep apnoea, and cancer; mortality; and resolution of hypertension and T2DM. Weight
measures were available for 3,847 patients between 1 and 4 mo, 2,884 patients between 5
and 12 mo, and 2,258 patients between 13 and 48 mo post-procedure. Bariatric surgery
patients exhibited rapid weight loss for the first four postoperative months, at a rate of 4.98
kg/mo (95% CI 4.88–5.08). Slower weight loss was sustained to the end of 4 y. Gastric
bypass (6.56 kg/mo) and sleeve gastrectomy (6.29 kg/mo) were associated with greater ini-
tial weight reduction than gastric banding (2.77 kg/mo). Protective hazard ratios (HRs) were
detected for bariatric surgery for incident T2DM, 0.68 (95% CI 0.55–0.83); hypertension,
0.35 (95% CI 0.27–0.45); angina, 0.59 (95% CI 0.40–0.87);MI, 0.28 (95% CI 0.10–0.74);
and obstructive sleep apnoea, 0.55 (95% CI 0.40–0.87). Strong associations were found
between bariatric surgery and the resolution of T2DM, with a HR of 9.29 (95% CI 6.84–
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12.62), and between bariatric surgery and the resolution of hypertension, with a HR of 5.64
(95% CI 2.65–11.99). No association was detected between bariatric surgery and fractures,
cancer, or stroke. Effect estimates for mortality found no protective association with bariatric
surgery overall, with a HR of 0.97 (95% CI 0.66–1.43). The data used were recorded for the
management of patients in primary care and may be subject to inaccuracy, which would
tend to lead to underestimates of true relative effect sizes.
Conclusions
Bariatric surgery as delivered in the UK healthcare system is associated with dramatic
weight loss, sustained at least 4 y after surgery. This weight loss is accompanied by sub-
stantial improvements in pre-existing T2DM and hypertension, as well as a reduced risk of
incident T2DM, hypertension, angina, MI, and obstructive sleep apnoea. Widening the
availability of bariatric surgery could lead to substantial health benefits for many people who
are morbidly obese.
Introduction
The prevalence of obesity and related health problems is increasing [1]. Worldwide, over 600
million adults are obese, with a body mass index (BMI) of 30 kg/m2 or more [2]. Bariatric sur-
gery is recommended for consideration in the United Kingdom and United States in people
with a BMI of 40 kg/m2 or more and in people with a BMI of 35–40 kg/m2 plus additional obe-
sity-related co-morbidities such as type 2 diabetes mellitus (T2DM), and for whom other
weight control measures have failed. Bariatric surgery is also considered first line therapy in
people with a BMI of 50 kg/m2 or more [3–5]. More recently, UK guidelines extended eligibility
for bariatric surgery to include people with a BMI of 30–34.9 kg/m2 and recent T2DM [6].
Evidence for the effectiveness of bariatric surgery is primarily based on the results of rando-
mised trials [7–10]. However, trials simultaneously measuring the effects of different surgery
methods are scarce, and it is unclear how evidence from trials translates to population-based
healthcare. As bariatric surgery is now being offered more to people with T2DM, the effective-
ness of treatment in these patients needs to be better defined. We therefore used data from the
UK Clinical Practice Research Datalink (CPRD) to characterise the association between bariat-
ric surgery and weight, BMI, and a wide range of relevant clinical outcomes including diabetes,
cardiovascular diseases (CVDs), fractures, cancer, and mortality.
Methods
Ethics
Scientific approval was obtained from the Medicines and Healthcare products Regulatory
Agency’s Independent Scientific Advisory Committee, and ethical approval was granted by the
London School of Hygiene & Tropical Medicine ethics committee.
Clinical Practice Research Datalink
The CPRD contains anonymised information from UK general practitioners and includes ~8%
of the UK population [11]. Information includes complete recording of consultations, diagno-
ses, prescribed medicines, and basic demographic data. The practices and patients are generally
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representative of the UK population [11], and data quality is subject to rigorous audits. The
data have been used to conduct over 700 peer-reviewed published studies, and data validity has
been shown to be high for a variety of diagnoses [12]. Measures of BMI are broadly representa-
tive, comparable with nationally representative UK survey data [13]. Data for this study were
taken from all CPRD records to the end of December 2014. We originally intended to use
linked data from Hospital Episode Statistics records to measure short-term outcomes following
surgery and linked data from the Myocardial Ischaemia National Audit Project for ischaemic
outcomes (see S3 Text), but insufficient linked data were available for this to be feasible.
Overview of Methods
Selection of the analysis population was done in four stages summarised here and with further
detail below. (1) We began by selecting patients with a record of undergoing bariatric surgery.
(2) We then selected a pool of obese patients without surgery, matched to surgery patients by
age, sex, general practice, and calendar period, with five non-surgery patients selected for each
surgery patient. (3) Amongst these patients, we calculated a propensity score for receiving sur-
gery based on a wide range of risk factors. (4) Each surgery patient was then matched 1:1 with
the non-surgery patient with the closest propensity score. All further analyses were then con-
ducted using the propensity-score-matched cohort. This staged process of population selection
was used to avoid the need for calculating propensity scores for the entire CPRD population.
Bariatric Surgery Group
Patients were included if they had a code indicating bariatric surgery during their registration
period in the CPRD (see S1 Text for code list) and had at least 12 mo of prior registration in
the CPRD before the date of the surgery, to ensure that any outcomes identified reflected inci-
dent events and not retrospective recording [14]. Patients were excluded if they previously had
a record indicating reversal of bariatric surgery (e.g., gastric band removal).
Eligible Comparison Group
A base comparison group was initially identified from the CPRD comprising individuals with
at least one measure of BMI 40 kg/m2 at any point in their registration, in order to define a
group of people who may have been eligible for bariatric surgery. The maximum follow-up
duration for patients was 15 y, and non-surgery patients remained eligible if they also had mea-
sures of BMI below 40 kg/m2 recorded during their follow-up. The non-surgery group was
therefore not restricted to patients for whom all measures of BMI were40 kg/m2. All eligible
bariatric surgery patients were then matched with up to five of these individuals, matching on
age (within 2.5 y), sex, general practice, and presence in the CPRD on the date bariatric surgery
was recorded (termed the index date). Non-surgery patients had to have no record of bariatric
surgery before this date and at least 12 mo of prior registration in the database.
Outcomes
The outcomes were change in weight and BMI; incident diagnoses of T2DM, hypertension,
angina, myocardial infarction (MI), stroke, fractures, obstructive sleep apnoea, and cancer;
mortality; and resolution of hypertension and T2DM.
Height and weight records were extracted from clinical files. Implausible records for obese
adults were discarded (any weight<40 kg or>300 kg;<1% all recorded weight measures).
Weights between 225 and 300 kg were discarded if other measures on the same day were<225
kg or where the ratio to other recorded weights for the individual was>1.5 (<0.01% of all
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recorded weight measures). For patients with recorded height, BMI was calculated for each
weight record, and the nearest weight prior to the index date was taken as the baseline weight.
For clinical outcomes, Read codes were used to identify records indicating incident events.
Hypertension and T2DM resolution were defined by either a code stating resolution or the
withdrawal of drug treatment for the condition for at least a 6-mo period.
Covariates
CPRD records were searched for records of T2DM, hypertension, coronary heart disease, cere-
brovascular disease, peripheral vascular disease, other atheroma, smoking status, alcohol con-
sumption, and use of statins, oral antidiabetic drugs (OAD), and insulin.
Propensity Score Matching
For all bariatric surgery patients and their matches, a conditional logistic regression model was
constructed with bariatric surgery as the outcome, and status regarding the following factors
defined prior to the index date as covariates: T2DM, hypertension, coronary heart disease,
cerebrovascular disease, peripheral vascular disease, other atheroma, smoking status, alcohol
consumption, and use of insulin, OADs, and statins. For variables with missing data (smoking
and alcohol consumption), a missing category was used in the analysis, since multiple imputa-
tion cannot be used in conjunction with propensity scores. Propensity scores were then calcu-
lated, and each surgery patient was matched 1:1 to the person without surgery with the closest
propensity score, choosing matches at random where more than one possible match had the
same score. All further analyses were done using this propensity-score-matched cohort. Stan-
dardised differences (differences in means or proportions divided by standard error) were cal-
culated for each baseline variable to determine any imbalances [15], with differences>0.2
suggesting imbalance.
Statistical Analysis
Weight and BMI changes. Non-surgery patients tended not to have a recent weight mea-
sure on their matched index date. To avoid errors associated with using out-dated measures
[13], follow-up for this group was started at the weight measured nearest to the index date and
ended at the earliest of 4 y later, death, bariatric surgery, first orlistat or sibutramine prescrip-
tion, transfer from practice, or last data recording date. Change in weight and BMI after bariat-
ric surgery was modelled using mixed effects linear regression.
The rate of weight loss was anticipated to change with time since surgery, and so a linear
spline model was fitted to allow the calculation of an approximate rate of change in each dis-
tinct phase of weight loss. The Akaike information criterion was used to determine the optimal
number and time point of spline knots. A restricted cubic spline model was later fitted after
advice from peer review, to avoid sharp discontinuity in rate measures, and both models are
presented. Right censoring was at the last recorded weight within 4 y of the index date. From
the final linear spline model, weight and BMI change and their 95% confidence intervals for
the study population were estimated over 4 y. Separate analyses were conducted in patients
with T2DM or CVD because of the specific importance of weight reduction therapies among
these groups [5]. The weight and BMI change associated with each surgical procedure was
measured separately where patient numbers permitted. For each surgery type, we compared
baseline BMI and used ANOVA to determine any differences. Post hoc we also assessed the
weight and BMI change for each surgery type separately in patients with T2DM, given recent
changes to UK guidelines.
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To determine whether changes in weight over time were biased by preferentially observing
later measures for patients whose baseline weight systematically differed from the group as a
whole, the baseline weight of patients contributing measures beyond 4 and 12 mo was com-
pared with the baseline weight of all patients.
Clinical outcomes. For clinical outcomes, Cox regression was used to determine the haz-
ard ratio (HR) for each event. For all analyses, the highest and lowest 5% propensity score
bands were excluded (trimming) since patients treated contrary to extreme scores can intro-
duce bias if important information about their health status is missing [16]. A sensitivity analy-
sis was done without trimming. For each analysis, all individuals with a history of the specific
outcome were excluded. We ensured that the proportional hazards assumption was met for all
analyses. Bariatric surgery patients were compared with propensity-score-matched non-sur-
gery individuals, with no statistical adjustments made, starting follow-up at the index date.
Right censoring was applied using the earliest of these events: the outcome of interest, death,
transfer away from the practice, or the last data collection date for the practice. For resolution
of T2DM and hypertension, analyses were restricted to individuals with a history of each con-
dition at the index date. Secondary analyses assessed the association between bariatric surgery
and each outcome in patients with either T2DM or any CVD, and for each subtype of bariatric
surgery where numbers permitted. Following peer review, a separate analysis of mortality
within 30 d of surgery was also conducted, to assess any association between bariatric surgery
and short-term mortality (to investigate peri-operative mortality). Initially, incident fatty liver
was also included as an outcome, but following peer review, this was removed because of a lack
of reliable diagnostic information on the more important outcome of non-alcoholic
steatohepatitis.
Post hoc we explored the results seen for T2DM resolution by examining HbA1c levels,
where recorded. After finding no protective association between bariatric surgery and mortal-
ity, we looked separately at the first year of follow-up and the remainder, since others have
reported delayed protective associations [17].
Health Survey for England estimates that currently 1.4 million residents in England are
morbidly obese (BMI 40 kg/m2) [18]. For all outcomes where an association with surgery
was detected, we estimated the absolute number of outcomes that surgery could potentially
prevent, by applying the relative risks obtained in our analysis to the rate of events detected in
the non-surgery group, and scaling to 1.4 million people.
All analyses were conducted using Stata 13.0 (StataCorp).
Results
A total of 4,036 patients were identified with a record of bariatric surgery (Fig 1). After apply-
ing exclusion criteria, 3,914 remained. Of these, 3,882 were matched on age, sex, practice, and
calendar period to 18,333 patients without bariatric surgery from a total population of 194,021
people with any single BMI measure of40 kg/m2. No matches were identified for 32 patients.
Propensity scores were then calculated for the age-, sex-, practice-, and calendar-period-
matched patients. Following this, each surgery patient was matched to the patient without sur-
gery with the closest propensity score. The distribution of baseline characteristics for this final
matched cohort is shown in Table 1. The mean age was 45 y, and 81% were women, with mean
follow-up of 3.4 y. There were 1,425 surgery patients who were followed for more than 4 y
(maximum 14 y). Standardised differences show that the distribution of all characteristics was
very similar between the groups, with the exception of BMI. Nearly all (99.5%) of the bariatric
surgeries performed were gastric band, gastric bypass, or sleeve gastrectomy. Bariatric surgery
patients had a mean BMI of 44.7 kg/m2, compared with 42.1 kg/m2 amongst patients without
Bariatric Surgery: A United Kingdom Cohort Study
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surgery. In the non-surgery group, 56% had a record of receiving a lifestyle intervention for
weight loss, most frequently advice about food intake (40%). However, the absence of a record
of receiving a lifestyle intervention should not be interpreted as a lack of intervention as it is
likely such advice is not well recorded.
Fig 1. Flow diagram of study population.
doi:10.1371/journal.pmed.1001925.g001
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Table 1. Background characteristics of propensity-score-matched cohort of patients with and without bariatric surgery.
Characteristic Bariatric Surgery Group (n =
3,882)
No Surgery Group (n =
3,882)
Standardised
Difference
Age (y), mean (SD) 45 (11) 45 (11) 0.012
Female, n (percent) 3,126 (80.5%) 3,166 (81.6%) −0.026
Years of follow-up after index date, mean (SD) 3.4 (2.3) 3.4 (2.4) 0.013
Smoking, n (percent)
Non-smoker 1,724 (44.4%) 1,725 (44.4%) −0.005
Current smoker 564 (14.5%) 532 (13.7%) 0.025
Ex-smoker 1,592 (41.0%) 1,623 (41.8%) −0.013
Missing 2 (0.1%) 2 (0.1%) −0.013
Alcohol consumption, n (percent)
Non-drinker 628 (16.2%) 608 (15.7%) 0.016
Ex-drinker 371 (9.6%) 349 (9.0%) 0.019
Current drinker: amount not known 21 (0.5%) 21 (0.5%) 0.000
Current drinker: <2 units/d 984 (25.4%) 956 (24.6%) 0.017
Current drinker: 3–6 units/d 1,278 (32.9%) 1,351 (34.8%) −0.042
Current drinker: >6 units/d 262 (6.8%) 256 (6.6%) 0.008
Missing 338 (8.7%) 341 (8.8%) −0.003
Last BMI (kg/m2) before index date
Mean (SD) 44.7 (8.8) 42.1 (6.5) 0.342
Number (percent) missing 59 (1.5%) 67 (1.7%)
Lag to index date (d), mean (SD) 278 (558) 539 (829)
Co-morbidities and drugs used, n (percent)
CVD 53 (1.4%) 40 (1.0%) 0.031
Coronary heart disease 145 (3.7%) 135 (3.5%) 0.015
Peripheral vascular disease 24 (0.6%) 27 (0.7%) −0.007
Other atheroma * (0%) * (0%) 0.013
Hypertension 1,313 (33.8%) 1,323 (34.1%) −0.004
T2DM: diagnosed or treated 1,320 (34.0%) 1,296 (33.4%) 0.012
T2DM: OAD treatment 824 (21.2%) 686 (17.7%) 0.090
T2DM: insulin treatment 252 (6.5%) 256 (6.6%) −0.003
Statin use 1,015 (26.2%) 987 (25.4%) 0.017
Type of bariatric surgery, n (percent)
Gastric band 1,829 (47.1%)
Gastric bypass 1,421 (36.6%)
Sleeve gastrectomy 613 (15.8%)
Duodenal switch * (0.1%)
Gastric stapling 6 (0.2%)
Stomach partition (not elsewhere classiﬁed) 5 (0.1%)
Mason vertical banded gastroplasty * (0.1%)
Lifestyle intervention for non-surgery group, n
(percent)
Any intervention 2,153 (56%)
Diet advice 1,535 (40%)
Seen by diet specialist 800 (21%)
Activity/exercise advice 793 (20%)
Non-speciﬁc 420 (11%)
*Counts <5 cannot be given precisely due to anonymity considerations.
SD, standard deviation.
doi:10.1371/journal.pmed.1001925.t001
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Change in Weight and BMI
For all weight and BMI analyses, figures show the results obtained from restricted cubic spline
models and tables show the results from linear spline models. Amongst surgery patients, the 4
mo following surgery saw rapid weight loss, with a mean rate of 4.98 kg/mo (95% CI 4.88–
5.08) (Fig 2; Table 2). Slower weight loss continued for the remaining follow-up. When strati-
fied by surgery type (Fig 2; Table 2), gastric bypass was associated with the largest initial weight
reduction rate, 6.56 kg/mo in the first 4 mo. Patients with sleeve gastrectomy had similar
results, with a weight reduction rate of 6.29 kg/mo, while gastric band was associated with a
less dramatic reduction of 2.77 kg/mo. There was no evidence of weight gain to the end of 4 y
in any group. People with CVD or T2DM had more rapid initial weight loss, contrary to expec-
tations [19] (Fig 2; Table 2), so we stratified the data by surgery type in patients with T2DM
and CVD. Amongst people with T2DM, gastric bypass was more prevalent than in the wider
group (49% versus 36%), as was sleeve gastrectomy (19% versus 16%), with fewer undergoing
gastric band (27% versus 47%). When stratified by surgery type, the results in people with
T2DM were largely similar to those seen in the group as a whole, with the exception of patients
who underwent sleeve gastrectomy: these patients gained an average of 0.21 kg/mo from 13 mo
onwards (S1 Table). Similarly, patients with CVD were more likely to have gastric bypass
(44%), with fewer having gastric bands (39%) or sleeve gastrectomy (15%); however, there
were insufficient patients with CVD to perform stratified analyses.
The mean baseline BMI for each surgery type was as follows: gastric band, 42.3 kg/m2; gas-
tric bypass, 46.9 kg/m2; and sleeve gastrectomy, 47.1 kg/m2. Using ANOVA, there was evidence
that these differences were more than expected by chance (p 0.001). As expected, the pattern
for BMI during follow-up closely followed that for weight in all analyses (Fig 2; Table 2).
The mean weight of surgery patients at baseline was 124 kg (standard deviation [SD] = 28
kg). For those contributing weight measures past 4 mo (n = 2,152) and 12 mo (n = 1,604),
mean baseline weight was 127 kg (SD = 28 kg) and 128 kg (SD = 28 kg), respectively, indicating
that patients with later weight measures were representative of the whole group in terms of
baseline weight.
Amongst the group without bariatric surgery, no overall changes in weight or BMI were
detected over the 4-y period.
Clinical Outcomes
Strong protective associations were detected between bariatric surgery and T2DM onset
(HR = 0.68, 95% CI 0.55–0.83), first treatment with an OAD (HR = 0.26, 95% CI 0.18–0.37),
first treatment with insulin (HR = 0.22, 95% CI 0.11–0.43), hypertension onset (HR = 0.35,
95% CI 0.27–0.45), angina onset (HR = 0.59, 95% CI 0.40–0.87), MI (HR = 0.28, 95% CI 0.10–
0.74), and obstructive sleep apnoea onset (HR = 0.55, 95% CI 0.37–0.82) (see Table 3). We also
found strong associations between bariatric surgery and the resolution of T2DM (HR = 9.29,
95% CI 6.84–12.62) and hypertension (HR = 5.64, 95% CI 2.65–11.99). HbA1c measures were
evaluated post hoc for patients discontinuing diabetes treatment. Measures were available for
236 (74%) surgery patients: for 144 (45%) patients, all subsequent measures were<6.0%, while
92 (29%) patients had at least one measure 6.0% after the estimated date of resolution. No
association was seen between bariatric surgery and stroke, fractures, cancer, or mortality. The
sensitivity analysis with all patients with extreme propensity scores included had very similar
results (S2 Table). When stratified by surgery type, the pattern with respect to outcomes was
similar for each type, with the exception of the outcomes T2DM and hypertension resolution,
where stronger associations were seen for gastric bypass and sleeve gastrectomy than for gastric
banding (S3 Table). The post hoc analysis for mortality, stratified on follow-up period, found a
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HR of 1.10 (95% CI 0.59–2.06) for the first year after surgery and 0.77 (95% CI 0.48–1.24) after
the first year. In the analysis of mortality within 30 d of surgery, fewer than five surgery patients
(0.08%) died, compared with no deaths in the non-surgical group (because of CPRD restric-
tions around patient anonymity, counts of less than five cannot be given precisely).
Absolute Effects
Assuming the associations we report are causal, the number of events that bariatric surgery
could have prevented amongst the ~1.4 million morbidly obese people in England over the
same period as this study is as follows: hypertension, n = 79,780; angina, n = 10,949; T2DM, n
= 41,600; MI, n = 4,861; and obstructive sleep apnoea, n = 12,299. Furthermore, disease resolu-
tion might have occurred in 107,807 people with T2DM and 13,464 people with hypertension.
Discussion
We assessed outcomes following bariatric surgery for obesity in routine clinical practice among
the general UK population. Amongst patients with an average BMI of 44.7 kg/m2, dramatic
reductions in weight and BMI were sustained over a 4-y period, with gastric bypass and sleeve
gastrectomy associated with greater weight loss than gastric band. Estimated 4-y weight loss
was 38 kg for gastric bypass, 31 kg for sleeve gastrectomy, and 20 kg for gastric band.
We found evidence that surgery has major beneficial associations with several clinical out-
comes, with reductions in risk seen for incident T2DM, hypertension, angina, MI, and obstruc-
tive sleep apnoea. Resolution of T2DM and hypertension was also seen. Crude estimates
suggest that large numbers of obese people could avoid future harmful clinical outcomes if they
were offered surgery. Although we acknowledge that not all patients are suitable for bariatric
Fig 2. Estimated mean change in weight and BMI over 4 y following bariatric surgery or no surgery.Dashed lines show 95%CIs.
doi:10.1371/journal.pmed.1001925.g002
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surgery, it appears that better access to bariatric surgery, where appropriate, could lead to a
considerable reduction in the burden of disease and substantial cost savings for the health sys-
tem. Notably, only 5,558 bariatric procedures were done in the UK in 2013, compared with
37,300 in France, where the prevalence of obesity is lower than in the UK [20]. Similarly, whilst
154,276 bariatric procedures were performed in the US and Canada in 2013, an estimated 6.4%
of the adult US population has a BMI 40 kg/m2, equating to around 14 million people, many
of whom could likely benefit from surgery [21].
On the whole, the outcomes seen following surgery were similar in people with T2DM.
There was a suggestion that people with T2DM undergoing sleeve gastrectomy may start to
regain weight a year after surgery. However, this was a post hoc analysis and would need to be
investigated further in other populations.
Resolution of T2DM and hypertension was more common in people receiving gastric
bypass or sleeve gastrectomy than in those undergoing gastric band surgery. For other out-
comes, there was little evidence of differential associations by surgery type.
Table 2. Rate of change in weight and BMI over 3-y follow-up.
Intervention and Follow-Up
Period
N at Follow-Up
Period Start
N with Weight
Measure
Estimated Weight Change, kg/
mo (95% CI)
Estimated BMI Change, kg/m2/
mo (95% CI)
Bariatric surgery (any form)
1–4 mo 3,882 3,847 −4.98 (−5.08 to −4.88) −1.78 (−1.82 to −1.75)
5–12 mo 3,372 2,884 −1.01 (−1.08 to −0.96) −0.37 (−0.39 to −0.35)
13–48 mo 3,020 2,258 −0.04 (−0.08 to 0.00) −0.01 (−0.03 to 0.00)
Gastric band
1–4 mo 1,881 1,828 −2.77 (−2.92 to −2.62) −1.00 (−1.04 to −0.94)
5–12 mo 1,758 1,165 −0.84 (−0.93 to −0.76) −0.30 (−0.33 to −0.27)
13–48 mo 1,626 961 −0.05 (−0.09 to 0.00) −0.02 (−0.03 to 0.00)
Gastric bypass
1–4 mo 1,535 1,489 −6.56 (−6.69 to −6.42) −2.36 (−2.40 to −2.31)
5–12 mo 1,368 1,172 −1.50 (−1.59 to −1.42) −0.55 (−0.58 to −0.52)
13–48 mo 1,201 890 0.02 (−0.04 to 0.08) 0.01 (−0.01 to 0.03)
Sleeve gastrectomy
1–4 mo 663 639 −6.29 (−6.55 to −6.04) −2.21 (−2.29 to −2.12)
5–12 mo 563 428 −0.97 (−1.13 to −0.80) −0.35 (−0.41 to −0.30)
13–48 mo 480 299 0.05 (−0.06 to 0.17) 0.03 (−0.01 to 0.06)
Bariatic surgery in patients
with CVD
1–4 mo 1,396 1,368 −5.40 (−5.54 to −5.25) −1.92 (−1.97 to −1.87)
5–12 mo 1,278 1,126 −0.96 (−1.05 to −0.87) −0.35 (−0.38 to −0.32)
13–48 mo 1,148 911 −0.09 (−0.14 to −0.03) −0.03 (−0.05 to −0.01)
Bariatric surgery in patients
with T2DM
1–4 mo 1,338 1,294 −5.65 (−5.79 to −5.50) −2.00 (−2.05 to −1.95)
5–12 mo 1,220 1,094 −0.98 (−1.07 to −0.89) −0.35 (−0.38 to −0.32)
13–48 mo 1,084 866 0.00 (−0.05 to 0.06) 0.00 (−0.02 to 0.02)
No intervention
1–12 mo 3,882 3,877 −0.11 (−0.14 to −0.08) −0.04 (−0.05 to −0.03)
13–24 mo 3,592 2,044 0.07 (0.03 to 0.12) 0.03 (0.01 to 0.04)
25–48 mo 3,176 1,510 −0.01 (−0.04 to 0.02) 0.00 (−0.01 to 0.01)
doi:10.1371/journal.pmed.1001925.t002
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Strengths andWeaknesses
This is one of the largest population-based studies examining a wide range of outcomes follow-
ing bariatric surgery. The data are representative of the UK population and reflect current med-
ical practice, and so the results are likely to generalise to the UK population as a whole. Patients
are not lost to follow-up in the CPRD; they remain registered with their practice unless they
transfer to another, at which point their follow-up is censored. This occurred in only ~10% of
the patients included here, reducing the potential for biased results due to selective loss to fol-
low-up.
Table 3. Association between bariatric surgery and health outcomes.
Outcome Group N* Number (Percent) with Outcome Median Follow-Up (y) HR (95% CI) p-Value
T2DM
First diagnosis No surgery 2,552 237 (6.6%) 2.9 —
Surgery 2,397 158 (9.3%) 3.1 0.68 (0.55–0.83) <0.001
First OAD No surgery 2,891 149 (4.7%) 2.9 —
Surgery 3,141 37 (1.3%) 3.2 0.26 (0.18–0.37) <0.001
First insulin No surgery 3,463 47 (1.3%) 3.0 —
Surgery 3,514 10 (0.3%) 3.1 0.22 (0.11–0.43) <0.001
Resolution No surgery 1,175 47 (4.0%) 2.6 —
Surgery 1,113 321 (28.8%) 1.8 9.29 (6.84–12.62) <0.001
Hypertension
Diagnosis No surgery 2,498 219 (8.8%) 2.8 —
Surgery 2,444 79 (3.2%) 2.9 0.35 (0.27–0.45) <0.001
Resolution No surgery 1,256 8 (0.6%) 2.8 —
Surgery 1,255 46 (3.7%) 2.8 5.64 (2.65–11.99) <0.001
Angina No surgery 3,565 68 (1.9%) 3.0 —
Surgery 3,463 40 (1.2%) 3.0 0.59 (0.40–0.87) 0.007
MI No surgery 3,732 18 (0.5%) 3.0 —
Surgery 3,618 5 (0.1%) 3.1 0.28 (0.10–0.74) 0.01
Stroke No surgery 3,748 19 (0.5%) 3.0 —
Surgery 3,683 17 (0.5%) 3.0 0.91 (0.47–1.76) 0.86
Fractures
Hip No surgery 3,749 7 (0.2%) 3.0 —
Surgery 3,686 8 (0.2%) 3.1 1.15 (0.42–3.18) 0.78
Wrist No surgery 3,566 18 (0.5%) 3.0 —
Surgery 3,486 27 (0.8%) 3.0 1.56 (0.86–2.84) 0.14
Spine No surgery 3,753 11 (0.3%) 3.0 —
Surgery 3,694 16 (0.4%) 3.0 1.50 (0.69–3.23) 0.30
Any No surgery 3,535 32 (0.9%) 3.0 —
Surgery 3,447 39 (1.1%) 3.0 1.26 (0.79–2.01) 0.34
Obstructive sleep apnoea No surgery 3,637 71 (2.0%) 3.0 —
Surgery 3,248 36 (1.1%) 3.1 0.55 (0.37–0.82) 0.004
Any cancer No surgery 3,536 138 (3.9%) 2.9 —
Surgery 3,452 127 (3.7%) 3.0 0.94 (0.74–1.20) 0.64
Mortality No surgery 3,774 50 (1.4%) 3.0 —
Surgery 3,714 53 (1.4%) 3.1 0.97 (0.66–1.43) 0.87
*Each analysis population consisted of patients without the condition of interest at the start of follow-up.
doi:10.1371/journal.pmed.1001925.t003
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BMI recorded in the CPRD has good concordance with the Health Survey for England at
the population level when using BMI measured within 3 y [13]. For our study, measures were
applied on the date taken, except baseline weight for the surgery group, where the most recent
pre-surgery measure was used. The average time from measurement to surgery was less than 1
y, and we therefore do not anticipate major bias. Although weight measures were not available
for all patients after surgery, the majority of patients remaining in follow-up did have valid
measures that could be included in our analyses. Patients contributing weight measures were
similar to those without measures, suggesting there were no systematic differences determining
whether weight was recorded.
Our case definition for T2DM and hypertension resolution was based on discontinuation of
pharmacological treatment because measures of HbA1c and blood pressure were not routinely
recorded for all patients. It is possible that these outcomes were subject to some inaccuracy,
which would tend to lead to underestimation of any change in risk following surgery.
At baseline, average BMI was lower in the non-surgery group, and some in this group had a
BMI below 40 during follow-up. This may have led to underestimation of relative effect sizes if
this reduction in BMI conferred a general protective effect on the non-surgery group, although
the groups were well matched on other co-morbidities. Mean baseline BMI was also a little
lower in people undergoing gastric banding than in those undergoing gastric bypass or sleeve
gastrectomy, and so caution is needed when interpreting potentially different results across
surgery types.
We were unable to look in detail at short-term adverse outcomes associated with surgery,
other than short-term mortality, which was very low (0.08%). However, the UK National Bar-
iatric Surgery Registry recently reported detailed short-term adverse outcomes from 18,283
bariatric surgery procedures conducted in the UK and Ireland between 2011 and 2013, comple-
menting the longer term outcomes we report here [22] and based largely on the same underly-
ing population. They reported an in-hospital mortality rate of 0.07%, similar to our findings.
The average post-operative hospital stay was 2.7 d, with only 3% remaining in hospital longer
than 5 d. The surgical complication rate for primary operations was 2.9%, with the most com-
mon complications cited as vomiting/poor intake, fluid/electrolyte problems, and pneumonia
and other infections. Cardiovascular complications were rare (0.3%). Procedure-related com-
plications, e.g., band slippage, bleeds, and obstructions, were reported in 2.4% of patients, and
revision surgery was required in 1.4% of cases. Revision surgery was most common for gastric
bands (1.8%) and was rarer for gastric bypass (0.4%) and sleeve gastrectomy (0.4%). There was
little difference between the procedures for other factors. Most other studies have suggested
that sleeve gastrectomy may be safer than gastric bypass [23–27], though some found no rele-
vant differences [28]. These findings suggest that adverse outcomes after bariatric surgery are
rare, hospital stays are short, and the benefits we report here outweigh the short-term risks
involved.
Comparison with Other Studies
A recent meta-analysis of randomised trials comparing surgery against non-surgical interven-
tions found that an additional 26 kg was lost by surgery patients, but highlighted that evidence
beyond 2 y was lacking [29]. Estimates of absolute weight lost in trials of gastric bypass range
from to 29.4 to 50.6 kg over 2 y [9,10,30,31]. For gastric band, estimates range from 17 to 21.1
kg [32,33], and for sleeve gastrectomy, from 25.1 to 29.5 kg [18,21]. Picot et al. [34] compared
evidence for different surgery types and concluded that gastric bypass was more effective than
gastric band. Evidence for differences between gastric bypass and sleeve gastrectomy is less
clear [17,35–37].
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A US observational cohort reported a 3-y weight reduction of 20 kg for gastric band patients
and 41 kg for gastric bypass patients [38]. Although longer term follow-up is available from the
Swedish Obese Subjects (SOS) study, direct comparison is difficult as the majority underwent
vertical banded gastroplasty, which was rarely used in our study [39].
Our results are similar to those in the studies described above. Moreover, our findings are
remarkably similar to the results reported in the US cohort [38], demonstrating the strength of
routine primary care records for measuring outcomes following bariatric surgery.
For other clinical outcomes, our findings are largely in line with the results of other studies,
though we did not find the strong protective association between bariatric surgery and mortal-
ity seen by others [17], possibly because of the lack of longer term data in our study. Notably,
the results of our post hoc analysis were consistent with a survival benefit a year after surgery—
similar to the long-term protective effect seen in the SOS study [34]—but this survival benefit
did not reach statistical significance. The effect estimates we report for resolution of T2DM
and hypertension are slightly weaker than those seen in some studies, but are consistent with
effects seen in the SOS study, and it is clear that this effect size has varied in other studies
depending on the case definition used [39–41]. Few studies have reported on vascular out-
comes, with most reporting associations of bariatric surgery with vascular risk factors instead
[42]. Our results suggest a slightly stronger protective association between surgery and MI than
reported in the SOS study [43], though the mix of surgery subtypes varies considerably between
our studies and could explain these differences. Notably, we found no association between bar-
iatric surgery and the risk of stroke.
Similar to Booth et al. [44], who also used data from the CPRD, we found a protective asso-
ciation between bariatric surgery and T2DM onset, although the HR of 0.68 we detected was
weaker than the HR of 0.2 previously reported. It is possible that this difference reflects a differ-
ence in the case definition used for T2DM, but, notably, we confirm a similarly strong protec-
tive association between surgery and first OAD treatment for T2DM, with a HR of 0.28.
Few studies have accurately measured the effects of surgery on cancer, with the exception of
the SOS study, which found a strong protective effect in women but not men [45]. We found
no such association here, although it is possible we had insufficient follow-up to detect any gen-
uinely causal effect, which may take many years to accrue, or that any benefits are cancer-site-
specific [46].
Longer term measures of outcomes following surgery are needed. This will require several
years’more data to accrue, especially for gastric bypass and sleeve gastrectomy.
Conclusion
Bariatric surgery as delivered in the UK healthcare system leads to dramatic weight loss, gener-
ally sustained at least 4 y after surgery. This weight loss is accompanied by substantial improve-
ments in pre-existing T2DM and hypertension as well as a reduced risk of incident T2DM,
hypertension, angina, MI, and obstructive sleep apnoea. Our results also suggest possible differ-
ences in outcomes following specific types of bariatric surgery amongst people with T2DM
that need to be investigated in other populations.
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Editors' Summary
Background
Obesity—having an unhealthy amount of body fat—is a growing threat to global public
health. Worldwide, 13% of adults are obese, and, in the UK and the US, the statistics are
even worse. A quarter and a third, respectively, of adults in these countries are obese. Obe-
sity is defined as having a body mass index (BMI; an indicator of body fat calculated by
dividing a person’s weight in kilograms by their height in meters squared) of30 kg/m2.
Compared to people with a healthy weight (a BMI of 18.5–24.9 kg/m2), overweight and
obese people have an increased risk of developing type 2 diabetes, cardiovascular condi-
tions such as hypertension (high blood pressure), myocardial infarction (heart attack),
angina, and stroke, and they tend to die younger. People become overweight, and eventu-
ally obese, by consuming food and drink that contain more energy (calories) than they
need for their daily activities. So, obesity can be prevented and reversed by eating less and
exercising more.
WhyWas This Study Done?
People with severe obesity (BMI of 40 kg/m2 or more) who have tried but failed to control
their weight through lifestyle changes sometimes undergo bariatric surgery (weight loss
surgery). In the UK and the US, this approach is also recommended for obese individuals
who have an obesity-related illness such as type 2 diabetes with a lower BMI of 35 kg/m2
or more. Techniques such as gastric band surgery, gastric bypass, and sleeve gastrectomy
all lead to reduced energy intake, and in randomized controlled trials comparing bariatric
surgery and lifestyle interventions, bariatric surgery is associated with greater weight loss.
However, the results of clinical trials are not always replicated in routine clinical practice.
Here, the researchers investigate whether there is an association between bariatric surgery
and weight, BMI, and obesity-related co-morbidities (illnesses) in the UK by undertaking
a retrospective cohort study (an observational study that compares recorded clinical out-
comes in non-randomized groups of patients who received different treatments).
What Did the Researchers Do and Find?
The researchers used the UK Clinical Practice Research Datalink, which contains anon-
ymized clinical information about patients provided by general practitioners (primary
care physicians), to identify 3,882 patients who had had bariatric surgery. They matched
each patient (average BMI 44.7 kg/m2), according to the patient’s medications and constel-
lation of risk factors, to an obese individual from the dataset who had not had bariatric
surgery. This “propensity matching” technique is used in studies where patients are not
allocated at random to receive a treatment, and is meant to control for confounding—the
possibility that patients who receive the treatment may be otherwise distinct from patients
who do not. According to this analysis, patients who had had bariatric surgery lost weight
rapidly during the first four post-operative months (4.98 kg/month); their weight loss was
sustained at a slower rate for up to four years. By contrast, there were no weight changes in
the patients who did not have surgery. Notably, bariatric surgery was associated with a
lower risk of type 2 diabetes onset, hypertension onset, angina onset, myocardial infarc-
tion, and obstructive sleep apnea (a sleep disorder) onset, and with the resolution of both
type 2 diabetes and hypertension in those who already had these conditions when they
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underwent surgery. However, over an average of 3.4 years of follow-up, there was no evi-
dence of any difference in the risk of death.
What Do These Findings Mean?
These findings show that bariatric surgery delivered in routine clinical practice in the UK
is associated with a substantial initial weight loss that is sustained for at least four years
after surgery. They also show that bariatric surgery is associated with improvements in
pre-existing type 2 diabetes and hypertension and with a reduced risk of developing sev-
eral obesity-related co-morbidities. Because the data used in the study were recorded for
patient management by primary care physicians, the researchers were unable to use strict
diagnostic criteria for some outcomes, which may limit the accuracy of these findings.
Nevertheless, these results suggest that widening the availability of bariatric surgery in the
UK could provide substantial health benefits for many people who are morbidly obese.
Indeed, the researchers calculate that, if the associations seen in this study are causal (an
observational study cannot prove that a treatment causes a specific outcome), bariatric
surgery could prevent and/or resolve many tens of thousands of cases of hypertension and
type 2 diabetes and prevent similar numbers of cases of other obesity-related illnesses
among the 1.4 million morbidly obese people living in the UK.
Additional Information
This list of resources contains links that can be accessed when viewing the PDF on a device
or via the online version of the article at http://dx.doi.org/10.1371/journal.pmed.1001925.
• TheWorld Health Organization provides information on obesity (in several languages)
• The Institute for Health Metrics and Evaluation website provides the latest details about
global obesity trends; the World Obesity Federation also provides information about the
global obesity epidemic
• The UK National Health Service Choices website provides information about obesity
(including some real stories), bariatric surgery (including some comments from
patients), and healthy eating
• The US Centers for Disease Control and Prevention has information on all aspects of
overweight and obesity
• ChooseMyPlate.gov is a resource provided by the US Department of Agriculture that
provides individuals and healthcare professionals with user-friendly information on
nutrition and physical exercise
• The US National Institute of Diabetes and Digestive and Kidney Diseases provides infor-
mation on bariatric surgery and on weight control and healthy living
• MedlinePlus provides links to other sources of information on obesity and bariatric
surgery (in English and Spanish)
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